84 results
Page 2 of 5
6-K
EX-99.3
001d9x 1xl8d7qdl6l2m
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
z8osfpm9jseebb cik
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
hmc m0qqwh
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
3sbtrch
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
fx76ffp8vbse69nmv2
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K/A
EX-99.1
brmx66a79m
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
v7gsub qxj
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
4t483xeaui0ro
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
vhn734thai1snvwg0pbe
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
xchmkbuq w1wvt
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
5pvjxc2uh8 ksj
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
uky9p mxtbu
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.2
tjyb65u1
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.3
yg06hbllxq uww
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.4
6a3nz8rwto3ojtl7
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
qm78d159eza63
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
p8mnlk8ptku uj2
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
D
73qnccowjif30
28 Jul 22
$140M in equity, sold $140M, 8 investors
4:57pm
6-K
EX-99.1
39tmgfd
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.1
na11d 2ydlkr
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm